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Homocysteine is a non-proteinogenic amino acid playing key roles in two 
interconnected metabolic pathways, namely, the activated methyl cycle and the linear 
trans-sulfuration pathway that allows the conversion of methionine to cysteine. A 
dysregulation of intracellular homocysteine metabolism could yield an increased export 
of this amino acid, leading to hyperhomocysteinemia, which has been associated with 
an increased risk of cardiovascular diseases. In spite of decades of experimental effort, 
there is no definitive consensus on what could be the molecular mechanisms whereby 
hyperhomocysteinemia could contribute to cardiovascular disease. The redox active 
nature of homocysteine has favored the idea of an induction of oxidative stress as the 
underlying mechanism of homocysteine toxicity. In contrast, homocysteine can also 
behave as an anti-oxidant. The present work is aimed to further analyze the capacity of 
homocysteine to modulate the redox capacity of both endothelial and tumor cells. 
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